Abiopharma

🔍 Venker Eric (Executive)

Company: Roivant Sciences Ltd. (ROIV)

Report Date: 2025-12-09

Detailed Transactions and Holdings:

• Acquired 200,000 shares of Common Shares at $3.85 per share (Direct)
  Date: 2025-12-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,697,908.00 | transaction_form_type: 4
• Sold 200,000 shares of Common Shares at $20.85 per share (Direct)
  Date: 2025-12-09 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,497,908.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 200,000 shares of Stock Option (Right to Buy) at $3.85 per share (Derivative)
  Date: 2025-12-09 | Code: M | Expires: 2032-04-19 | equity_swap_involved: 0 | shares_owned_after: 5,876,523.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
• F2: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).